ArticleFrontiers in surgery2026
Clinical and imaging differentiation of intrapancreatic accessory spleen from pancreatic neuroendocrine tumor and solid-pseudopapillary tumor: a retrospective analysis.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrapancreatic accessory spleen (IPAS) represents a rare anatomical variant of the spleen that is misdiagnosed as pancreatic neoplastic lesions. Notably, IPAS is often erroneously identified as pancreatic neuroendocrine tumor (PNET) or solid pseudopapillary tumor (SPT), which consequently results in unnecessary resection of the pancreas. This study aimed to summarize the clinical, imaging and laboratory characteristics of these lesions, clarify the key differential diagnostic points among them, and thereby enhance the clinical understanding and preoperative diagnostic accuracy of IPAS. Methods: This retrospective study analyzed all 7 cases of IPAS diagnosed at our hospital from January 2008 to December 2025. For comparative analysis, consecutive patients with pathologically confirmed PNET ( Results: IPAS was distinguished from PNET and SPT primarily by consistent location in the pancreatic tail (100%), frequent heterogeneous arterial-phase enhancement with CT attenuation often similar to the spleen, universal adjacency to the splenic vessels, solid consistency, and predominantly reddish-brown gross appearance, with most lesions showing a soft texture. In contrast, PNET and SPT showed more variable location, enhancement patterns, attenuation relative to spleen, vessel contact rates, and pathologic color/texture. SPTs are typically larger and more frequently exhibit calcification. Conclusion: For lesions located in the pancreatic tail, adjacent to the spleen, and exhibiting heterogeneous enhancement in the arterial phase, the possibility of IPAS should be thoroughly considered. Nevertheless, surgical resection remains rational and appropriate when preoperative evaluation cannot completely exclude the possibility of PNET, SPT, or other pancreatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.